VRAY News and Press, ViewRay Inc. From 11/10/22

ViewRay® to Present at the Stifel 2022 Healthcare Conference PR Newswire DENVER , Nov. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake , Pre...

The following slide deck was published by ViewRay, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: ViewRay, Inc. 2022 Q3 - Results - Earnings Call Presentation

ViewRay, Inc. (VRAY) Q3 2022 Results Conference Call November 01, 2022 05:00 PM ET Company Participants Matt Harrison - Director, IR Scott Drake - President & CEO Zach Stassen - CFO Dr. Paul Strong - VP of Clinical Affairs Conference Call Participan...

ViewRay press release ( NASDAQ: VRAY ): Q3 GAAP EPS of -$0.14 in-line. Revenue of $26.5M (+38.2% Y/Y) beats by $1.69M . The Company is again raising the bottom end of its revenue guidance from $90 million to $94 million, and reiterated the top end of the range of $...

ViewRay press release ( NASDAQ: VRAY ): Q3 GAAP EPS of -$0.14. Revenue of $26.49M (+38.1% Y/Y). FY2022 Outlook : The company is again raising the bottom end of its revenue guidance from $90M to $94M, and reiterated the top end of the range of $104M vs. consensus of...

ViewRay Announces Third Quarter 2022 Results PR Newswire DENVER , Nov. 1, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022...

ViewRay ( NASDAQ: VRAY ) on Thursday said its MRIdian system was better than CT-guided system in reducing toxicity in Stereotactic Body Radiotherapy (SBRT) for localized prostate cancer. The company reported main goal data from a phase 3 trial called MIRAGE w...

MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer PR Newswire Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- v...

ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients PR Newswire Study's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes u...

MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022 PR Newswire Clinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies DENVER , Oct. 19, 2022 /PRNewswire/ -- ViewRay, Inc....